---
title: Antidotes and Specific Treatments
type: content
phase: 1
status: complete
priority: high
tags: [toxicology, antidotes, N-acetylcysteine, naloxone, flumazenil, fomepizole, chelation, specific-treatments]
created: 2025-11-08
last_modified: 2025-11-08
---

# Antidotes and Specific Treatments

## Introduction

Antidotes are agents that counteract the effects of poisons through various mechanisms including chelation, competitive antagonism, bypassing metabolic blocks, or providing alternative pathways. While supportive care is the foundation of toxicology management, specific antidotes can be life-saving in select poisonings.

## General Principles

**Antidote Mechanisms**:
1. **Receptor antagonism**: Naloxone (opioids), flumazenil (benzodiazepines)
2. **Chelation**: EDTA (lead), deferoxamine (iron)
3. **Metabolic competitor**: Fomepizole (ethylene glycol)
4. **Bypassing metabolic block**: Methylene blue (methemoglobinemia)
5. **Supplying deficient substrate**: N-acetylcysteine (acetaminophen)
6. **Immunotherapy**: Digoxin-specific antibodies

**Limitations**:
- Few poisonings have specific antidotes
- **Supportive care** remains cornerstone
- Antidotes may have toxicity

---

## Acetaminophen Overdose

### N-Acetylcysteine (NAC, Mucomyst, Acetadote)

**Mechanism**:
- **Replenishes glutathione (GSH)**
- **Directly binds NAPQI** (toxic metabolite)
- Provides sulfate for sulfation pathway

**Indications**:
1. **Acetaminophen overdose** (>150 mg/kg or toxic level)
2. Use **Rumack-Matthew nomogram** (if acute, single ingestion, known time)

**Nomogram**:
- Plot acetaminophen level vs. time post-ingestion
- **Above treatment line** (150 mcg/mL at 4 hours) → treat
- **Cannot use** if: Unknown time, chronic ingestion, extended-release

**Dosing**:

**IV** (Preferred):
- **Loading**: 150 mg/kg over 1 hour
- **Second**: 50 mg/kg over 4 hours
- **Third**: 100 mg/kg over 16 hours
- **Total**: 300 mg/kg over 21 hours

**Oral**:
- **Loading**: 140 mg/kg
- **Maintenance**: 70 mg/kg q4h × 17 doses
- **Total**: 1330 mg/kg over 72 hours

**Efficacy**:
- **Most effective <8 hours** post-ingestion
- **Still beneficial 24-48 hours** (if severe toxicity, ongoing liver injury)
- **Near 100% effective** if started <8 hours

**Adverse Effects**:
- **Anaphylactoid reactions** (IV, especially loading):
  - Flushing, rash, bronchospasm, hypotension
  - **Slow infusion** if occurs
  - NOT true allergy (can rechallenge)
- Nausea, vomiting (oral - smells like rotten eggs)

**Monitoring**:
- **Acetaminophen level** (q4-24h until undetectable)
- **AST, ALT, INR** (hepatotoxicity markers)
- **Continue NAC** if ALT rising or INR elevated

**Clinical Pearls**:
- **Start empirically** if high suspicion (don't wait for level)
- **Effective up to 24-48 hours** (continue if liver injury)
- **IV preferred** (better tolerability, severe cases)
- **Pregnancy**: Safe, treat normally

---

## Opioid Overdose

### Naloxone (Narcan)

**Mechanism**: **Competitive antagonist** at μ, κ, δ opioid receptors

**Indications**:
1. **Opioid overdose**: Respiratory depression, CNS depression
2. **Diagnostic** (if unclear etiology)

**Clinical Features** (Opioid Toxidrome):
- **Miosis** (pinpoint pupils)
- **Respiratory depression** (life-threatening)
- **CNS depression** (sedation, coma)

**Dosing**:
- **Initial**: 0.4-2 mg IV/IM/SC/IN
- **Repeat**: q2-3min until response (up to 10 mg)
- **Continuous infusion**: 2/3 of awakening dose per hour (long-acting opioids)

**Response**:
- **Rapid** (1-2 minutes IV, 5-10 minutes IN/IM)
- **Reversal of respiratory depression** (goal, not full consciousness)
- **Diagnostic**: Response confirms opioid toxicity

**Duration**:
- **Short half-life** (30-90 minutes)
- **Shorter than most opioids** → **re-sedation risk**
- **Observe 4-6 hours** minimum (longer for long-acting opioids)

**Adverse Effects**:
- **Acute withdrawal** (chronic users):
  - Agitation, vomiting, diarrhea, tachycardia, hypertension
  - **Pulmonary edema** (rare, severe)
- **Use minimal effective dose** (titrate to breathing, not consciousness)

**Special Considerations**:

**Buprenorphine** (partial agonist):
- May require **higher doses** naloxone (tight binding)

**Intranasal (Narcan Nasal Spray)**:
- **4 mg** per spray
- **Easy administration** (lay public, EMS)
- **Bystander use** (opioid epidemic)

**Take-Home Naloxone**:
- Prescribe to high-risk patients (opioid users, post-overdose)
- **Harm reduction** strategy

**Clinical Pearls**:
- **Give to anyone with respiratory depression** (if opioid suspected)
- **Titrate to breathing** (not full consciousness - avoid withdrawal)
- **Re-sedation common** (observe, repeat doses)
- **Safe in pregnancy** (opioid reversal saves fetus)

---

## Benzodiazepine Overdose

### Flumazenil (Romazicon)

**Mechanism**: **Competitive antagonist** at benzodiazepine binding site (GABA-A receptor)

**Indications**:
1. **Reversal of procedural sedation** (diagnostic/therapeutic procedures)
2. **Benzodiazepine overdose** (selected cases)

**Contraindications** (Important):
- **Chronic benzodiazepine use** (precipitates withdrawal, seizures)
- **Seizure disorder**
- **TCA co-ingestion** (unmasks TCA toxicity → seizures, arrhythmias)
- **Elevated ICP** (benzodiazepines protective)

**Dosing**:
- **Initial**: 0.2 mg IV over 30 seconds
- **Repeat**: 0.3 mg, then 0.5 mg q1min (max 3 mg total)

**Response**: Rapid (1-2 minutes)

**Duration**: Short (45-90 minutes) → **re-sedation** possible

**Adverse Effects**:
- **Seizures** (chronic users, TCA co-ingestion)
- **Withdrawal syndrome**
- Agitation, anxiety

**Clinical Use**:
- **Rarely indicated** in overdose (supportive care usually sufficient)
- **Risk > benefit** in most overdoses
- **Useful** for procedural sedation reversal (known pure benzodiazepine)

**Clinical Pearl**: **Avoid in most overdoses** (seizure risk, supportive care effective)

---

## Methanol and Ethylene Glycol Poisoning

### Fomepizole (Antizol, 4-Methylpyrazole)

**Mechanism**: **Competitive inhibitor of alcohol dehydrogenase (ADH)**
- Prevents toxic metabolite formation:
  - **Methanol** → formaldehyde, formic acid (blindness, acidosis)
  - **Ethylene glycol** → glycolic acid, oxalic acid (nephrotoxicity, acidosis)

**Indications**:
1. **Methanol poisoning**
2. **Ethylene glycol poisoning**

**Advantages over Ethanol**:
- **No CNS depression** (vs. ethanol infusion)
- **Easier dosing** (predictable kinetics)
- **No hypoglycemia** (ethanol causes in children)
- **Preferred antidote**

**Dosing**:
- **Loading**: 15 mg/kg IV
- **Maintenance**: 10 mg/kg q12h × 4 doses, then 15 mg/kg q12h
- **Continue** until methanol/ethylene glycol <20 mg/dL

**Hemodialysis**:
- **Adjunct therapy** (removes parent compound and toxic metabolites)
- **Indications**: Acidosis, renal failure, high levels
- **↑Fomepizole dose** during dialysis (removed)

**Adverse Effects**: Headache, nausea (generally well-tolerated)

**Clinical Pearl**: **Superior to ethanol** (preferred antidote)

### Ethanol (Alternative)

**Mechanism**: Competitive substrate for ADH (same as fomepizole)

**Dosing**:
- **Loading**: 600-800 mg/kg (10 mL/kg of 10% ethanol IV)
- **Maintenance**: 80-150 mg/kg/h (adjust to blood ethanol 100-150 mg/dL)

**Disadvantages**:
- CNS depression, hypoglycemia (children)
- Difficult to dose (individual variation)
- Requires frequent monitoring

**Status**: **Fomepizole preferred** (if available)

---

## Organophosphate/Carbamate Poisoning

**Mechanism**: Acetylcholinesterase inhibition → cholinergic excess

### Atropine

**Mechanism**: **Muscarinic receptor antagonist**
- **Reverses muscarinic effects** (not nicotinic)

**Cholinergic Toxidrome**:
- **Muscarinic**: SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis)
  - Plus: Miosis, bronchospasm, bradycardia
- **Nicotinic**: Muscle fasciculations, weakness, paralysis
- **CNS**: Confusion, seizures, coma

**Dosing**:
- **Initial**: 1-2 mg IV (double q5min until drying of secretions)
- **May require massive doses** (tens to hundreds of mg)
- **Endpoint**: Drying of bronchial secretions (not pupil size)

**Note**: Does **NOT reverse nicotinic** effects (muscle weakness) or reactivate enzyme

### Pralidoxime (2-PAM)

**Mechanism**: **Reactivates acetylcholinesterase** (if not aged)
- **Breaks organophosphate-enzyme bond**
- **Reverses nicotinic AND muscarinic** effects

**Indications**:
- **Organophosphate poisoning** (not carbamates)
- **Severe cases** (muscle weakness, respiratory failure)

**Dosing**:
- **Loading**: 1-2 g IV over 30 minutes
- **Continuous infusion**: 500 mg/h (or bolus 1-2 g q4-6h)

**Timing**: Must give **before aging** (permanent covalent bond, 24-48 hours)

**Clinical Pearl**: **Give both atropine + pralidoxime** for organophosphates

---

## Iron Overdose

### Deferoxamine (Desferal)

**Mechanism**: **Iron chelator**
- Binds free iron → **ferrioxamine** → renal excretion
- **Urine turns "vin rosé" color** (pink/orange)

**Indications**:
1. **Iron overdose** (>60 mg/kg elemental iron or symptomatic)

**Clinical Features** (Iron Toxicity):
- **Stage 1** (0-6h): GI (nausea, vomiting, diarrhea, abdominal pain)
- **Stage 2** (6-24h): Latent (apparent improvement)
- **Stage 3** (12-48h): Shock, acidosis, hepatotoxicity
- **Stage 4** (2-6 weeks): GI scarring, obstruction

**Dosing**:
- **15 mg/kg/h IV continuous infusion**
- **Max 6-8 g/day**
- **Continue** until asymptomatic, acidosis resolved, iron level normal

**Adverse Effects**:
- **Hypotension** (rapid infusion)
- **ARDS** (high doses, prolonged)
- **Yersinia sepsis** (iron-dependent organism)
- Allergic reactions

**Monitoring**: Iron level, acidosis (anion gap)

**Clinical Pearl**: **Vin rosé urine** confirms ferrioxamine excretion

---

## Lead Poisoning

### Chelators

#### Succimer (DMSA, Chemet)

**Mechanism**: Chelates lead (and other heavy metals)

**Advantages**:
- **Oral** (outpatient therapy)
- **Less toxic** than EDTA, BAL

**Indications**:
- **Mild-moderate lead poisoning** (children: BLL 45-69 mcg/dL)
- **Adults**: Symptomatic

**Dosing**: 10 mg/kg PO q8h × 5 days, then q12h × 14 days

#### EDTA (Edetate Calcium Disodium)

**Mechanism**: Chelates lead

**Indications**:
- **Severe lead poisoning** (children: BLL ≥70 mcg/dL, encephalopathy)
- **Adults**: Severe

**Dosing**: 1000 mg/m2/day IV/IM × 5 days

**Adverse Effects**: Nephrotoxicity, hypocalcemia

**Note**: **Use with dimercaprol** (BAL) if encephalopathy

#### Dimercaprol (BAL, British Anti-Lewisite)

**Mechanism**: Chelates lead, mercury, arsenic

**Indications**:
- **Severe lead poisoning** (with EDTA)
- **Mercury, arsenic poisoning**

**Route**: IM only (painful)

**Adverse Effects**: Hypertension, tachycardia, painful injection, garlic breath

**Clinical Pearl**: **Succimer preferred** (oral, less toxic) if not severe

---

## Digoxin Toxicity

### Digoxin-Specific Antibody Fragments (Digibind, DigiFab)

**Mechanism**: **Binds digoxin** → inactivates → renal excretion of complex

**Indications**:
1. **Life-threatening digoxin toxicity**:
   - Severe arrhythmias (VT, VF, high-grade AV block)
   - Hyperkalemia (K+ >5.5 mEq/L)
   - Digoxin level >10-15 ng/mL (acute) or >5 ng/mL (chronic with symptoms)

**Dosing**:
- **Empiric**: 10-20 vials IV (if unknown amount)
- **Calculated**: Based on total body load
  - Vials = (Digoxin level × weight in kg) / 100

**Response**: Rapid (onset minutes, peak hours)

**Monitoring**:
- **Cannot use digoxin level** after administration (antibody-digoxin complex measured)
- **Monitor K+** (may ↓rapidly), **ECG**

**Adverse Effects**: Hypokalemia (rapid), allergic reactions (rare), heart failure exacerbation (loss of inotropy)

**Clinical Pearl**: **Life-saving** in severe toxicity

---

## Cyanide Poisoning

**Sources**: Fires (combustion of plastics, wool), industrial, sodium nitroprusside, amygdalin

**Mechanism**: Inhibits cytochrome c oxidase (Complex IV) → cellular hypoxia

### Hydroxocobalamin (Cyanokit)

**Mechanism**: **Binds cyanide** → cyanocobalamin (vitamin B12) → renal excretion

**Advantages**:
- **Safe** (no methemoglobinemia like sodium nitrite)
- **Rapid administration**
- **First-line**

**Dosing**: 5 g IV over 15 minutes (repeat 5 g if needed)

**Adverse Effects**:
- **Red discoloration** (skin, urine) - benign
- **Transient hypertension**
- **Interferes with lab tests** (colorimetric assays)

**Clinical Pearl**: **Preferred antidote** (safer than nitrites)

### Sodium Nitrite + Sodium Thiosulfate (Nithiodote)

**Mechanism**:
- **Sodium nitrite**: Induces methemoglobinemia → cyanide binds methemoglobin (instead of cytochrome c)
- **Sodium thiosulfate**: Provides sulfur for rhodanese → converts cyanide to thiocyanate

**Disadvantages**:
- **Methemoglobinemia** limits oxygen carrying capacity (dangerous in fire victims with CO poisoning)
- **Slower administration**

**Dosing**:
- Sodium nitrite: 300 mg IV
- Sodium thiosulfate: 12.5 g IV

**Status**: **Hydroxocobalamin preferred** (safer)

---

## Carbon Monoxide Poisoning

### Oxygen Therapy

**100% Oxygen** (Normobaric):
- **First-line treatment**
- **↓COHb half-life**: 5-6 hours (room air) → 60-90 minutes (100% O2)
- **Continue** until COHb <10% and asymptomatic

### Hyperbaric Oxygen (HBO)

**Mechanism**:
- **Further ↓COHb half-life** to 20-30 minutes
- **↑Dissolved O2** (tissue oxygenation despite COHb)
- **May ↓delayed neurologic sequelae**

**Indications** (Controversial):
- **Loss of consciousness**
- **Severe metabolic acidosis**
- **COHb >25%**
- **Pregnancy** (fetal COHb higher)
- **Cardiac ischemia**
- **Neurologic symptoms**

**Availability**: Limited (specialized centers)

**Clinical Pearl**: **100% O2 first-line** (HBO if available, severe cases)

---

## Methemoglobinemia

### Methylene Blue

**Mechanism**:
- **Cofactor for NADPH-methemoglobin reductase**
- Converts methemoglobin (Fe3+) → hemoglobin (Fe2+)

**Indications**:
- **Methemoglobin >20%** (symptomatic <20%)
- Symptomatic patients

**Dosing**: 1-2 mg/kg IV over 5 minutes (repeat if needed)

**Response**: Rapid (onset 30-60 minutes)

**Contraindications**:
- **G6PD deficiency** (causes hemolysis)
- **Screen G6PD** before giving if possible

**Adverse Effects**:
- Serotonin syndrome (SSRI interaction)
- Blue-green urine
- Hemolysis (G6PD deficiency)

**Clinical Pearl**: **Check G6PD** before giving (causes hemolysis if deficient)

---

## Other Important Antidotes

### Vitamin K (Phytonadione)

**Indications**: Warfarin overdose, vitamin K deficiency

**Dosing**: 10 mg IV/PO (higher doses for rodenticide poisoning)

### Protamine

**Indications**: Heparin reversal

**Mechanism**: Binds heparin (neutralizes)

**Dosing**: 1 mg protamine per 100 units heparin

### Calcium

**Indications**:
- **Calcium channel blocker overdose**
- **Hydrofluoric acid burns** (topical calcium gluconate gel, IV calcium)
- Hyperkalemia, hypocalcemia

### Glucagon

**Indications**: **Beta-blocker overdose** (bypasses β-receptor)

**Dosing**: 5-10 mg IV bolus, then 1-10 mg/h infusion

### Octreotide

**Indications**: **Sulfonylurea-induced hypoglycemia** (↓insulin release)

**Dosing**: 50-100 mcg SC/IV q6-12h

### Pyridoxine (Vitamin B6)

**Indications**:
- **Isoniazid overdose** (seizures refractory to benzodiazepines)
- **Ethylene glycol** (cofactor for alternative pathway)

**Dosing**: Gram-for-gram with INH ingested (or 5 g if unknown)

---

## Clinical Pearls

1. **N-acetylcysteine**: Acetaminophen overdose, most effective <8 hours, continue if liver injury
2. **Naloxone**: Opioid overdose, titrate to breathing (not consciousness), short duration (re-sedation)
3. **Flumazenil**: Rarely used (seizure risk), avoid chronic benzodiazepine users
4. **Fomepizole**: Methanol/ethylene glycol, superior to ethanol
5. **Atropine + pralidoxime**: Organophosphates, atropine for muscarinic, pralidoxime reactivates enzyme
6. **Deferoxamine**: Iron overdose, vin rosé urine
7. **Digoxin antibodies**: Life-saving in severe digoxin toxicity
8. **Hydroxocobalamin**: Cyanide (preferred over nitrites)
9. **Methylene blue**: Methemoglobinemia, check G6PD first
10. **Supportive care cornerstone** - few antidotes available

---

## Key Takeaways

1. **Supportive care** foundation of toxicology (most poisonings lack antidotes)
2. **N-acetylcysteine (NAC)**: Acetaminophen, replenishes glutathione, effective <8 hours
3. **Naloxone**: Opioid antagonist, titrate to breathing, short duration (re-sedation)
4. **Flumazenil**: Benzodiazepine antagonist, avoid chronic users (seizures)
5. **Fomepizole**: ADH inhibitor, methanol/ethylene glycol preferred antidote
6. **Atropine**: Organophosphates (muscarinic), pralidoxime (reactivates enzyme)
7. **Deferoxamine**: Iron chelator, vin rosé urine confirms ferrioxamine
8. **Digoxin antibodies**: Severe digoxin toxicity, binds and inactivates digoxin
9. **Hydroxocobalamin**: Cyanide, binds to form cyanocobalamin (B12)
10. **Methylene blue**: Methemoglobin reduction, contraindicated G6PD deficiency

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Goldfrank's Toxicologic Emergencies, 11th Edition
3. Poisindex® Toxicologic Managements (Micromedex)
4. Dart RC, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2006.
5. American Academy of Clinical Toxicology Practice Guidelines
